- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Subfoveal choroidal neovascularisation
- Meeting Date: July 2019
- Public Summary Document (PSD) July 2019 PBAC Meeting - (PDF 706KB)
- Public Summary Document (PSD) July 2019 PBAC Meeting - (Word 181KB)
Aflibercept – July 2019
Aflibercept: Solution for intravitreal injection 4 mg in 100 microlitres (40 mg per mL) vial, Solution for intravitreal injection 3.6 mg in 90 microlitres (40 mg per mL) pre-filled syringe; Eylea®
Last updated
1 November 2019